Alcohol detox for Highland Beach — CIWA-Ar-guided, medically supervised, discretion assured.

RECO Island's Delray Beach campus is a 12-minute drive up A1A from Highland Beach — closer than most Boca specialty practices. Residents of Bel Lido Isle, Toscana, and Ocean Cove receive physician-led medical detox with CIWA-Ar-scored benzodiazepine tapers, parenteral thiamine, and MAT initiation, then transition directly into small-census residential treatment on the same campus with the same team — no waitlists, no third-party handoffs.

Highland Beach occupies a three-mile oceanfront strip between Delray and Boca Raton, a 12-minute drive up A1A to RECO Island’s Delray Beach campus. For a resident of Bel Lido Isle, Toscana, Boca Cove, or Ocean Cove weighing where to admit for alcohol withdrawal, the operational question is not which facility has the nicest lobby — it is whether the setting is a medically supervised detox with 24/7 physician oversight or a lower-acuity program that will transfer to a hospital if things escalate. RECO Island runs the former: a small-census, physician-led medical detox followed by direct in-house transition to residential treatment, on the same campus, without waitlists or third-party handoffs.

Alcohol withdrawal is the one substance withdrawal that can kill you

Opioid withdrawal is miserable but not fatal in an otherwise healthy adult. Stimulant withdrawal is psychiatric — dysphoria, hypersomnia, cravings — not medically dangerous. Alcohol is the one substance whose withdrawal syndrome carries genuine mortality: seizures, delirium tremens, and cardiovascular collapse produce a small but real death rate in unsupervised withdrawal, with published case-fatality rates for untreated DTs still 1-4% even under modern management.

The strongest predictor of a serious event is a prior history of withdrawal seizures or DTs — the kindling phenomenon, in which repeated withdrawals produce progressively more severe neurologic events at lower thresholds. Additional risk factors include daily consumption above roughly 8-10 standard drinks, a use history measured in years, age above 60, concurrent benzodiazepine or sedative-hypnotic dependence, and medical comorbidities such as cardiomyopathy, cirrhosis, or significant electrolyte derangement. RECO Island stratifies risk at intake using history, vital signs, laboratory studies, and a baseline CIWA-Ar, then staffs the detox accordingly — which is why medical detox is the standard of care for alcohol use disorder in anyone with meaningful physiologic dependence, not a preference.

CIWA-Ar scoring and symptom-triggered benzodiazepine dosing

The Clinical Institute Withdrawal Assessment for Alcohol, revised — CIWA-Ar — is the ten-domain instrument that governs benzodiazepine dosing at RECO Island: nausea, tremor, paroxysmal sweats, anxiety, agitation, orientation and clouding of sensorium, tactile disturbances, auditory disturbances, visual disturbances, and headache. Nursing scores the CIWA-Ar every one to four hours during the acute window, and the score triggers medication rather than a fixed clock-based schedule.

Benzodiazepine selection is clinical. Chlordiazepoxide is the default long-acting agent for the uncomplicated patient because its self-tapering pharmacokinetics smooth the withdrawal curve. Lorazepam is preferred in cirrhosis or advanced hepatic disease because it lacks active metabolites and does not accumulate in liver failure. Diazepam is used when rapid onset is required for severe symptoms or seizure prophylaxis. Doses are titrated to CIWA-Ar suppression — typically targeting a score below 8 — and the taper is driven by symptom control rather than a preset calendar.

Symptom-triggered protocols consistently produce shorter treatment duration, lower total benzodiazepine exposure, and fewer breakthrough events than fixed-schedule dosing. A patient who does not need medication does not receive it; a patient whose CIWA-Ar rises is treated promptly rather than waiting for the next scheduled dose.

Thiamine, folate, and Wernicke prevention

Chronic alcohol use produces thiamine (vitamin B1) deficiency through poor dietary intake, impaired jejunal absorption, and reduced hepatic storage. Untreated deficiency produces Wernicke’s encephalopathy — the classical triad of ophthalmoplegia, ataxia, and confusion appears in fewer than 20% of cases, so clinical suspicion is required — and, if not corrected, Korsakoff’s syndrome, an anterograde and retrograde amnesia that does not reverse.

RECO Island’s admission protocol includes parenteral thiamine, typically 100 mg IM or IV on day one and continued through the acute window, alongside folate, a B-complex multivitamin, and magnesium replacement. Oral thiamine is inadequate in the actively drinking patient because gut absorption is unreliable — the parenteral route is what the pharmacology requires. Glucose is not administered before thiamine in the malnourished patient because a carbohydrate load can precipitate Wernicke’s in the thiamine-depleted brain.

Electrolyte correction — potassium, phosphate, magnesium — is routine, and a basic metabolic panel, hepatic panel, coagulation studies, and CBC are drawn on admission. Patients with cirrhotic changes, abnormal INR, or thrombocytopenia are managed within the medical detox rather than triaged elsewhere.

MAT initiation during detox and the transition to residential

Medical detox that ends at day seven with no ongoing pharmacology is a common failure pattern. RECO Island treats detox as day one of the medication-assisted treatment decision, not a separate episode. For alcohol use disorder, three FDA-approved medications are on the table, and the choice is individualized to the clinical picture rather than defaulted to whichever agent the facility stocks.

Naltrexone — 50 mg oral daily, or long-acting injectable Vivitrol at 380 mg IM monthly — is the first-line option for most patients. It blocks the mu-opioid receptor and blunts the reinforcing effect of alcohol; the COMBINE trial showed a modest but reproducible reduction in heavy-drinking days. Naltrexone requires a 7-10 day opioid-free window, which the detox stay provides by definition. Acamprosate at 666 mg three times daily modulates the glutamate/GABA rebalancing of post-acute withdrawal and is initiated after abstinence is stabilized; it is a reasonable choice in patients with concurrent opioid pain requirements or hepatic disease where naltrexone is contraindicated. Disulfiram is reserved for the highly motivated patient with a supervising partner, because its effect is entirely contingent on adherence.

Because the residential program continues on the same campus with the same physicians and nursing team, there is no discontinuity of care and no dropout window between detox and residential. The alcohol detox plan, the MAT decision, and the psychiatric and therapy schedule are documented as one clinical trajectory rather than three handoffs.

What to expect on admission from Highland Beach

Admission begins with a phone screen: use history, prior withdrawal events, current medical conditions, medications, and insurance. From Bel Lido Isle, Boca Cove, Ocean Cove, Toscana, or Penthouse, the drive up A1A is 12 minutes, and same-day admissions are often available when the screen and benefits verification complete during business hours.

Intake includes a physician history and physical, vital signs and orthostatic assessment, a blood draw for CBC, comprehensive metabolic panel, hepatic enzymes, and magnesium, and a urine drug screen. A baseline CIWA-Ar is scored, ASAM Criteria dimensions — intoxication and withdrawal potential, biomedical conditions, emotional/behavioral status, readiness, relapse risk, recovery environment — are documented, and the initial benzodiazepine, thiamine, and electrolyte plan is written before the first medication is administered. Nursing is 24/7; a physician sees the patient daily and is available around the clock for changes in clinical status.

Insurance and admissions from Highland Beach

RECO Island works with major commercial carriers, including Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and Blue Cross Blue Shield plans. Verification of benefits is completed before admission so the deductible, out-of-pocket maximum, and coverage of the residential level of care that follows detox are clear on day one rather than at discharge. For most Highland Beach residents on employer or ACA marketplace plans, medical detox and residential treatment are covered benefits when medical necessity is documented — which is the case for any patient meeting DSM-5 criteria for alcohol use disorder with physiologic dependence.

Utilization review is handled internally; the admissions and clinical teams document ASAM Criteria across all six dimensions so that authorization for continued stay is clinically defensible. Patients are not discharged for administrative reasons while clinical need continues, and the finance conversation is kept separate from the clinical one throughout the stay.

Serving residents of: Bel Lido Isle, Boca Cove, Ocean Cove, Toscana, Penthouse.